

## Chapter 1 | Biotechnology Products

[1.1] Biotech Products by Year of Approval (1980-2020).....	14
[1.2] Biotech Products Marketed in United States, plus European Union and Japan, by Product Category (12.31.2020).....	21
[1.3] Total Number of Biotech Products Approved in USA by Biotech Category – Summary Table of Molecules, Products, Indications and Companies (12.31.2020).....	35
[1.4] FDA Biotech Product Approvals in 5-Year Windows (1980-2020).....	36
[1.5] Biotech Product FDA Approvals over Time by Type of Product, (1980-2020).....	37
[1.6.1] Number of New Indications for Biotech Products by Decade (1982-2019).....	39
[1.6.2] Indications for Biotech Products by Medical Discipline (1982-2020).....	39
[1.6.3] Biotech Products' Approvals, % New Indications of Total Indications by Medical Discipline (1982-2020).....	40
[1.6.4] Individual Indications by Medical Disciplines (1980-2020).....	40
[1.6.5] Indications for Biotech Products over Time by Decade, (1982-2020).....	44
[1.6.6] Biotech Products listed based on their use in each Medical Discipline (USA, EU) (12.31.2020).....	45
[1.7.1] Blockbuster Biotech Products Worldwide (2001-2020).....	49
[1.7.2] Blockbuster Biotech WW Products Usage by Top Medical Disciplines (2011-2020).....	53
[1.8.1] Biosimilar Product Summary [Marketed products] – USA & Europe (1997-2020).....	54
[1.8.2] Biosimilar Product Summary [Marketed products] – USA & Europe - Medical Disciplines with # Products & # Indications (1998-2020).....	54
[1.8.3] Biosimilar Products - Further Company Engagement (1998-2020).....	55
[1.8.4] Biosimilar Products Marketed in European Union & USA (1997-2020).....	56
[1.9.1] Protein Products – Recombinant (USA – 147 Products + WW – 16) (1980-2020).....	59
[1.9.2.1] Protein Products – Recombinant – Number of FDA Approvals over Time in 5-Year Intervals (1985-2019).....	59
[1.9.2.2] Protein Products – Recombinant – No. of FDA Approvals over Time (1985-2020).....	60

[1.9.3] Protein Products – Recombinant – Type & Number of Host Cells [#138 Products] (USA) (1980-2020)	60
[1.9.4] Proteins (USA) – Recombinant – Special Properties [# Products] (1980-2020)	61
[1.9.5] Recombinant Proteins Products (in USA) by Uses in Medical Disciplines (1980-2020)	61
[1.10.1] Monoclonal Antibody Products – No. FDA Approved, in 5-Year Intervals (1985-2019)	62
[1.10.2] Monoclonal Antibodies in USA - Cumulative Number of Products FDA Approved over Time (2001-2020)	63
[1.10.3] Companies Marketing Monoclonal Antibodies – with Ranking [#126 Mabs - #45 companies] (1980-2020)	63
[1.10.4] # Mab Uses by Medical Disciplines (2001-2020)	64
[1.10.5] Mab Target Receptors (#64) with Diseases treated (2001-2020)	65
[1.10.6] Disease Abbreviations/Definitions for Mab Targets in Exhibit 1.10.5	66
[1.10.7] Mab Molecular Traits & Structures (2001-2020)	67
[1.11.1] Peptides – Number of FDA Product Approvals over Time in 5-Year Intervals (1978-2020)	68
[1.11.2] Peptides – No. of Products by Medical Disciplines (1978-2020)	69
[1.11.3] Peptides – No. of Indications for Peptides by Medical Disciplines (1978-2020)	69
[1.11.4] Peptides – Traits of Products (1978-2020)	69
[1.11.5] Peptides – Generic Products (12.31.2020)	70
[1.12.1] Biotech Product Vaccines – Traits & Companies (12.31.2020)	71
[1.12.2] Biotech Products – Vaccines (USA) – Target Organisms (12.31.2020)	72
[1.12.3] Biological Products – Vaccines (USA) – Target Organisms for Other non-Biotech Products (12.31.2020)	72
[1.13] Biotech Products – Other Categories (USA) (1980-2020)	73
[1.14] Biotech Product Withdrawals from Approval in USA (1985-2020)	74
[1.15.1] Annual Cost Estimates of Biotech Products – Top Products by Costs (2018-2020)	75
[1.15.2] Annual Estimated Costs of Biotech Products – Chronic Diseases – \$USD / Patient /Year (2018-2020)	77